Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Retifanlimab With Trastuzumab and Pertuzumab Combination in HER2-Addicted Breast Cancer

NCT07772245 is registered in ClinicalTrials.gov with Polly A. Niravath, MD as lead sponsor.

NCT NCT07772245
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07772245 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Retifanlimab With Trastuzumab and Pertuzumab Combination in HER2-Addicted Breast Cancer
Lead sponsor
Polly A. Niravath, MD
Phase
Phase 2
Overall status
Not yet recruiting
Start date
December 31, 2026
Completion date
December 31, 2032
Enrollment
30 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

her2-addicted breast cancer